Business
Onco-Innovations Welcomes AstraZeneca's Interest in Founding Role in PROmAI - an Inka-led AI-Oncology Consortium
VANCOUVER, BC / ACCESS Newswire / June 27, 2025 / Onco-Innovations Limited(CBOE CA:ONCO)(Frankfurt:W1H,WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that its wholly-owned subsidiary, Inka Health Corp. ("Inka Health"), has received ...
About this update from Onco-innovations Ltd.
[{"type":"text","content":"VANCOUVER, BC / ACCESS Newswire / June 27, 2025 / Onco-Innovations Limited(CBOE CA:ONCO)(Frankfurt:W1H,WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that its wholly-owned subsidiary, Inka Health Corp. ("Inka Health"), has received a formal Expression of Interest (EOI) from AstraZeneca plc (AstraZeneca), indicating its intent to participate as a founding member in the Predictive Oncology Outcomes using Multimodal AI (PROmAI) Consortium. PROmAI is being established as a strategic initiative to bring together leading global pharmaceutical companies and scientific experts to guide and inform Inka Health's development of next-generation AI solutions in oncology. AstraZeneca's involvement would reinforce the Consortium's vision of creating a high-impact, multi-stakeholder platform shaping the future of predictive cancer research.","length":893,"tagName":"p"},{"type":"text","content":"The PROmAI Consortium, initiated and led by Inka Health, is a collaborative initiative focused on advancing the development and validation of artificial intelligence methodologies to support improved prediction of oncology outcomes. Designed to address current limitations in translational modeling, particularly during the transition from early- to late-phase clinical development, the Consortium aims to bring together insights from pharmaceutical, data science, and clinical research communities. Inka Health is in active discussions with additional global pharmaceutical companies regarding potential participation in the Consortium and will provide further updates as progress is made.","length":690,"tagName":"p"},{"type":"text","content":"By combining real-world and clinical trial data-including molecular, clinical, imaging, and other multimodal datasets-with emerging techniques in causal AI, the Consortium seeks to foster innovation in predictive modeling, enhance interpretability and reliability of results, and contribute to frameworks aligned with regulatory and payer expectations. Participating members will collaborate on the design and execution of research activities that support the broader goal of improving trust, transparency, and utility of AI-driven insights in oncology drug development. For Inka Health, this Consortium represents a strategic opportunity to lead the advancement of AI method...